In accordance with our strategic plan and endorsed by our external advisors, the former Mouse Models Core has expanded to offer multiple imaging modalities and thus reorganized into the Small Animal Modeling and Imaging (SAMI) Core to reflect this improved, integrated focus. The primary purpose of the SAMI core is to provide proficient generation and examination of rodent models of cancer for basic and translational research. SAMI continues to provide specialized consultations and services for the derivation, characterization, and preservation of genetically-engineered mice, and a variety of tumor cell lines for xenograft and syngeneic transplant mouse models. Tumor development, progression, metastasis, and response to therapy in transgenic or transplanted mouse models of cancer can be evaluated using modern multimodality imaging including bioluminescent and biofluorescent imaging, ultrasound, magnetic resonance imaging, and beta particle imaging. Within the last funding period, the core has experienced significant growth, including the addition of imaging sen/ices, expert personnel, a new Scientific Director, acquisition of new lab space and capital equipment, and provision of several new services including an MRI, an ultrasound, bioluminescence and biofluorescence, beta-imaging, intravital microscopy, cryopreservation and rederivation, and ES cell culture. The Core requests CCSG Suppori of $17S,286, which is S1% of its operational budget. Over 80% of users were Moffitt members and peer-reviewed. Usage increased in all services. The core derived 66 founders or chimeras for 12 genetically engineered mouse models and cryopreserved or rederived 8 mouse lines. Genomic DNA was prepared from 774 mouse tail biopsies and genotyped via 20 hybridization blots. Twelve luciferase-expressing tumor cell lines were distributed for use in xenograft mouse models. In FY 2010, the Caliper IVIS workstations were utilized for 519 hours by 15 members;4S4 hours on the IVIS-200 and 85 hours on the IVIS-100. The Visual Sonics Vevo 2100 US system was used for 165 hours by six Pis. The Varian 7T MRI instrument was used for 486 hours by five investigators.

Public Health Relevance

The SAMI core provides proficient generation and examination of rodent models and tumor development, progression, metastasis, and response to therapy in transgenic or transplanted mouse models of cancer can be evaluated using modern multimodality imaging including bioluminescent and biofluorescent imaging, ultrasound, magnetic resonance imaging, and beta particle imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-15
Application #
8495987
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$97,989
Indirect Cost
$39,835
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612
Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :
Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880
Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Robinson, Lary A; Jaing, Crystal J; Pierce Campbell, Christine et al. (2016) Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer 115:497-504

Showing the most recent 10 out of 974 publications